Literature DB >> 8103161

Immunologically active proteins in intravenous immunoglobulin.

L Lam, C F Whitsett, J M McNicholl, T W Hodge, J Hooper.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8103161     DOI： 10.1016/0140-6736(93)91784-j

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  18 in total

Review 1.  Immunomodulatory action of intravenous immunoglobulin.

Authors:  W A C Sewell; S Jolles
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

2.  Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice.

Authors:  Eleanor Roy; Evangelos Stavropoulos; John Brennan; Stephen Coade; Elena Grigorieva; Barry Walker; Belinda Dagg; Ricardo E Tascon; Douglas B Lowrie; M Joseph Colston; Stephen Jolles
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 3.  Clinical uses of intravenous immunoglobulin.

Authors:  S Jolles; W A C Sewell; S A Misbah
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

Review 4.  Intravenous immunoglobulin and dendritic cells.

Authors:  Namita Misra; Jagadeesh Bayry; Jagadeesh Bayary; Sooryasarathi Dasgupta; Amal Ephrem; Jean-Paul Duong Van Huyen; Sandrine Delignat; Gazzala Hassan; Giuseppina Caligiuri; Antonino Nicoletti; Sebastien Lacroix-Desmazes; Michel D Kazatchkine; Srini V Kaveri
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 5.  Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

Authors:  Vir-Singh Negi; Sriramulu Elluru; Sophie Sibéril; Stéphanie Graff-Dubois; Luc Mouthon; Michel D Kazatchkine; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2007-03-11       Impact factor: 8.317

6.  Mechanisms of action of immune globulin.

Authors:  E Fernández-Cruz; D Alecsandru; S Sánchez Ramón; S S Ramón
Journal:  Clin Exp Immunol       Date:  2009-09       Impact factor: 4.330

7.  Recommendations for the use of albumin and immunoglobulins.

Authors:  Giancarlo Maria Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossettias
Journal:  Blood Transfus       Date:  2009-07       Impact factor: 3.443

Review 8.  Intravenous immunoglobulin in neurological disorders: a mechanistic perspective.

Authors:  Namita Misra; Jagadeesh Bayry; Amal Ephrem; Suryasarathi Dasgupta; Sandrine Delignat; Jean-Paul Duong Van Huyen; Fabienne Prost; Sebastien Lacroix-Desmazes; Antonino Nicoletti; Michel D Kazatchkine; Srini V Kaveri
Journal:  J Neurol       Date:  2005-05       Impact factor: 4.849

9.  Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use.

Authors:  S Kaveri; T Vassilev; V Hurez; R Lengagne; C Lefranc; S Cot; P Pouletty; D Glotz; M D Kazatchkine
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

10.  Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice.

Authors:  A Nicoletti; S Kaveri; G Caligiuri; J Bariéty; G K Hansson
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.